07/02/2013

Terapia adiuvante con trastuzumab in pazienti con carcinoma mammario iniziale HER-2 positivo

"Our study shows that women with small, node-negative HER2-positive breast cancer may benefit from trastuzumab therapy. These women actually have a significant risk of local recurrence in the breast after breast conservation therapy (~10%), but trastuzumab may reduce their risk to about 1%"
(Comment on: 
Kiess AP et al.: "Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer", Cancer. 2011 Sep 1. doi: 10.1002/cncr.26484. [Epub ahead of print])

Condividi
Altri articoli

Complicanze post-chirurgiche nelle pazienti operate per carcinoma mammario e aspetti riabilitativi

Condividi

Alterazioni del ritmo circadiano e rischio di carcinoma mammario

Condividi

Cadmio e rischio di neoplasia mammaria

Condividi

Radioterapia con protoni in donne affette da neoplasia mammaria

Condividi

L'antiepilettico fenitoina riduce la crescita cellulare e le metastasi del tumore mammario

Condividi